Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare

Ruth-Anne Langan, BA, Alberto Japp, PhD, Michael Gonzalez, PhD, Rozena Rasheed, BS, Sheila K Pierson, MS, Charlly Kao, PhD, Hakon Hakonarson, MD PhD, Frits van Rhee, MD PhD, Michael Betts, PhD, Taku Kambayashi, MD PhD, David C Fajgenbaum, MDMBA,MSc

Blood (2019) 134 (Supplement_1): 1046.

https://doi.org/10.1182/blood-2019-128994

Published: 2019

Journal Articles

Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center

Katie Stone, BS, Francisco Socola, MD, Amy Greenway, Samina Waheed, Kristen Carter, APRN, Diane Glendinning, APRN, Daisy Alapat, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 3701.

https://doi.org/10.1182/blood-2018-99-119510

Published: 2018

Journal Articles

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy

Robert Frank Cornell, MD, Samuel Z. Goldhaber, MD, Brian G Engelhardt, MD, Javid Moslehi, MD, Madan Jagasia, MD MS, Daryl Patton, Shelton Lacy Harrell, MSN, Robert L Hall, MSN, Houston Wyatt, PharmD, Gregory Piazza, MD

Blood (2018) 132 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2018-99-112577

Published: 2018

Journal Articles

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

David C. Fajgenbaum

Blood (2018) 132 (22): 2323–2330.

https://doi.org/10.1182/blood-2018-05-848671

Published: 2018

Journal Articles

Impact of Omitting Post-Transplant Mini-Methotrexate Doses in Allogeneic Hematopoietic Cell Transplantation: A Single-Center Retrospective Study

Andrew Lin, PharmD, Patrick Hilden, MS, Molly Maloy, MS, Ann A. Jakubowski, MD PhD, Esperanza B. Papadopoulos, MD, Craig S. Sauter, MD, Roni Tamari, MD, Doris Ponce, MD, Sergio A. Giralt, MD, Boglarka Gyurkocza, MD

Blood (2017) 130 (Supplement 1): 3255.

https://doi.org/10.1182/blood.V130.Suppl_1.3255.3255

Published: 2017

Journal Articles

A Case of Immunotactoid Glomerulopathy (ITG) Associated with Monoclonal B-Cell Lymphocytosis (MBL) with Chronic Lymphocytic Leukemia (CLL) Phenotype Treated with Obinutuzumab

Nino Aleksidze, MD, Michael B Stokes, MD, Alan P Skarbnik, MD

Blood (2017) 130 (Supplement 1): 5324.

https://doi.org/10.1182/blood.V130.Suppl_1.5324.5324

Published: 2017

Journal Articles

Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses

Christopher Sheild Nabel, MD PhD, Stephen Sameroff, BS, Dustin Shilling, PhD, Jason R Ruth, PhD, Mitsuhiro Kawano, MD, Yasuharu Sato, MD, Noriko Iwaki, MD, Federico Valdivieso, BS, Michael Feldman, MD, Katie Stone, BS, Daisy Alapat, MD, Frits van Rhee, MD PhD, Amy Chadburn, MD, Signe Spetalen, MD, Alexander Fosså, MD PhD, W. Ian Lipkin, MD, David C Fajgenbaum, MDMBA,MSc

Blood (2017) 130 (Supplement 1): 3589.

https://doi.org/10.1182/blood.V130.Suppl_1.3589.3589

Published: 2017

Journal Articles

Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes

Sheila K Pierson, MS, Aaron James Stonestrom, MDPhD, Jason R Ruth, PhD, Dustin Shilling, PhD, Hongzhe Li, PhD, Yue Ren, MS, Katie Stone, BS, Frits van Rhee, MD PhD, David C Fajgenbaum, MDMBA,MSc

Blood (2017) 130 (Supplement 1): 3592.

https://doi.org/10.1182/blood.V130.Suppl_1.3592.3592

Published: 2017

Journal Articles

Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach

David C Fajgenbaum, MDMBA,MSc, Dustin Shilling, PhD, Helen L Partridge, BS, Sheila K Pierson, MS, Jason R Ruth, PhD, Christopher Sheild Nabel, MD PhD, Katie Stone, BS, Vandana Chaturvedi, PhD, Michael B. Jordan, MD, Adam D. Cohen, MD, Vera Krymskaya, PhD, Arthur H Rubenstein, MBBCh, Frits van Rhee, MD PhD, Thomas S Uldrick, MDMS

Blood (2017) 130 (Supplement 1): 3593.

https://doi.org/10.1182/blood.V130.Suppl_1.3593.3593

Published: 2017

Journal Articles

Efficacy and Safety of Deferasirox in Chelation Naïve HbEβ Thalassemia Patients: Initial Experience from a Tertiary Centre of Eastern India

Debmalya Bhattacharyya, MDDM, Ranadip Chowdhury, MD, Soumita Choudhuri, Pramit Ghosh, MD, Maitreyee Bhattacharyya, DM

Blood (2017) 130 (Supplement 1): 4760.

https://doi.org/10.1182/blood.V130.Suppl_1.4760.4760

Published: 2017

Journal Articles

Ruxolitinib Used to Treat Hypereosinophilic Syndrome

Seung Lee, bs, Coby Palmares, Niko Koutsoukos, J. Brice Weinberg, MD, Trisa Palmares, MD, Alice Song, MD, Harold Song, MD, Sheila Benedicto, bs, Michael Song, bs, Vu Phan, MD, Julia Song, MD

Blood (2016) 128 (22): 5500.

https://doi.org/10.1182/blood.V128.22.5500.5500

Published: 2016

Journal Articles

Comparison of Laboratory Data of Patients with Tafro Syndrome and Idiopathic Multicentric Castleman Disease: A Japanese Retrospective Study

Shino Fujimoto, MD, Hiroshi Kawabata, MD PhD, Nozomu Kurose, MD PhD, Kazue Takai, MD PhD, Masaru Kojima, MD PhD, Norifumi Tsukamoto, MD PhD, Tomohiro Kinoshita, MD PhD, Shigeo Nakamura, MD PhD, Sadao Aoki, MD PhD, Yasufumi Masaki, MD PhD

Blood (2016) 128 (22): 4893.

https://doi.org/10.1182/blood.V128.22.4893.4893

Published: 2016

Journal Articles

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Blood (2016) 128 (22): 624.

https://doi.org/10.1182/blood.V128.22.624.624

Published: 2016

Journal Articles

Prospective Study of 168 Infants with Transient Abnormal Myelopoiesis with Down Syndrome: Japan Pediatric Leukemia/Lymphoma Study Group, TAM-10 Study

Hideki Muramatsu, MD PhD, Tomoyuki Watanabe, Daisuke Hasegawa, MD PhD, Park Myoung-ja, Shotaro Iwamoto, Takashi Taga, MD PhD, Etsuro Ito, MD PhD, Tsutomu Toki, PhD, Kiminori Terui, Ryu Yanagisawa, Katsuyoshi Koh, MD PhD, Akiko M. Saito, Keizo Horibe, MD PhD, Yasuhide Hayashi, MD PhD, Souichi Adachi, MD PhD, Shuki Mizutani, MD PhD, Kenichiro Watanabe

Blood (2015) 126 (23): 1311.

https://doi.org/10.1182/blood.V126.23.1311.1311

Published: 2015

Journal Articles

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Adam M. Petrich, MD, Leo I. Gordon, MD, Jeffrey R. Infante, MD, Sumit Madan, MD, Francis J. Giles, MD, Halla S. Nimeiri, MBBS, Jason B. Kaplan, MD, Kate Stumpo, Bin Zhang, ScD, Stephanie Faucette, PharmD, PhD, Yaping Shou, MD PhD, Kent C. Shih, MD

Blood (2015) 126 (23): 2693.

https://doi.org/10.1182/blood.V126.23.2693.2693

Published: 2015

Journal Articles

Novel C3 Mutation Causing Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab

Joao Carlos Guerra, MD PhD, Claudio Galvao de Castro, MD, Paulo Vidal Campregher, MD, Tatiana Galvao, MD, Oscar Pavao Santos, MD, Bento Cardoso Santos, MD, Luiz Vicente Rizzo, MD PhD, Flavia Munhoz Ferreira, MD, Michelle P. Silveira, MD, Nelson Hamerschlak, MD PhD, Helio Korkes, MD

Blood (2014) 124 (21): 1333.

https://doi.org/10.1182/blood.V124.21.1333.1333

Published: 2014

Journal Articles

In Vivo Modeling Of Genetic Mechanisms Associated With Sickle Cell Disease Nephropathy

Blair R Anderson, Erica E Davis, PhD, Marilyn J. Telen, MD, Allison E Ashley-Koch, PhD

Blood (2013) 122 (21): 2224.

https://doi.org/10.1182/blood.V122.21.2224.2224

Published: 2013

Journal Articles

A Novel Hybrid CFH/CFHR1–3 Gene in Atypical Hemolytic Uremic Syndrome

Mehmet F. Hepgur, MD, Preeti Chaudhary, MD, Sarmen Sarkissian, MD, Richard J. H. Smith, MD, Howard Liebman, MD, Ilene C Weitz, MD

Blood (2012) 120 (21): 4644.

https://doi.org/10.1182/blood.V120.21.4644.4644

Published: 2012

Journal Articles

Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,

Jorge E. Cortes, Franck E. Nicolini, MD, PhD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, Luke P. Akard, MD, Adam Craig, MD, PhD, Nisha Nanda, PhD, Carrie Dial, BS, Annie-Claude Benichou, MD, Katie Cairati, MS, Michele Baccarani, MD, Gerard T. Kennealey, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3761.

https://doi.org/10.1182/blood.V118.21.3761.3761

Published: 2011

Journal Articles

Durable Responses with Autologous Hematopoietic Stem Cell Transplantation in Patients with POEMS Syndrome

Krina Patel, MD, Robert Z. Orlowski, MD, PhD, Nina Shah, MD, Qaiser Bashir, MD, Yvonne T Dinh, Gabriela Rondon, MD, Sergio Giralt, MD, Richard Champlin, MD, Muzaffar H Qazilbash, MD

Blood (2011) 118 (21): 4522.

https://doi.org/10.1182/blood.V118.21.4522.4522

Published: 2011

NARROW

Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare

Personalized Therapy in Multicentric Castleman Disease Produces Excellent Outcomes in a Tertiary Referral Center

Prospective Study of Apixaban for Primary Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

Impact of Omitting Post-Transplant Mini-Methotrexate Doses in Allogeneic Hematopoietic Cell Transplantation: A Single-Center Retrospective Study

A Case of Immunotactoid Glomerulopathy (ITG) Associated with Monoclonal B-Cell Lymphocytosis (MBL) with Chronic Lymphocytic Leukemia (CLL) Phenotype Treated with Obinutuzumab

Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses

Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes

Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach

Efficacy and Safety of Deferasirox in Chelation Naïve HbEβ Thalassemia Patients: Initial Experience from a Tertiary Centre of Eastern India

Ruxolitinib Used to Treat Hypereosinophilic Syndrome

Comparison of Laboratory Data of Patients with Tafro Syndrome and Idiopathic Multicentric Castleman Disease: A Japanese Retrospective Study

Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Prospective Study of 168 Infants with Transient Abnormal Myelopoiesis with Down Syndrome: Japan Pediatric Leukemia/Lymphoma Study Group, TAM-10 Study

Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

Novel C3 Mutation Causing Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab

In Vivo Modeling Of Genetic Mechanisms Associated With Sickle Cell Disease Nephropathy

A Novel Hybrid CFH/CFHR1–3 Gene in Atypical Hemolytic Uremic Syndrome

Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,

Durable Responses with Autologous Hematopoietic Stem Cell Transplantation in Patients with POEMS Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only